130A.T
Veritas In Silico Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 434.00
+0.23%Aug 6, 2026, 02:20 UTC
Veritas In Silico opened the Kawasaki Research Institute in April 2026 by relocating and expanding facilities from the Shinkawasaki Research Institute, as part of strengthening its research infrastructure.
Source:Aug 6, 2026, 02:20 UTC
Veritas In Silico signed a contract with SpiroChem AG in May 2026 for joint exploratory research on mRNA-targeted compounds, following an agreement in December 2025.
Source:Aug 6, 2026, 02:20 UTC
Veritas In Silico announced its financial results for the second quarter of fiscal year ending December 2026 (January-June 2026), reporting a 15.5% year-on-year decrease in business revenue to 0.36 billion yen, an operating loss of 2.46 billion yen, an ordinary loss of 2.43 billion yen, and an interim net loss of 3.86 billion yen.
Source:Aug 6, 2026, 02:20 UTC
Veritas In Silico ended its joint research collaboration with Takeda Pharmaceutical Company in April 2026 after achieving certain results and mutual discussions.
Source: